Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1

15 Apr 2024

Abstract excerpt

Most available neutralizing antibodies are ineffective against highly mutated SARS-CoV-2 Omicron subvariants. Therefore, it is crucial to develop potent and broad-spectrum alternatives to effectively manage Omicron subvariants. Here, we constructed a high-diversity nanobody phage display library and identified nine nanobodies specific to the SARS-CoV-2 receptor-binding domain (RBD). Five of them exhibited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38675799
DOI: 10.3390/vaccines12040417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1PMID 38675799Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsSemantic proximity Read ↗

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2Semantic proximity Read ↗

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSemantic proximity Read ↗

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infectionSemantic proximity Read ↗

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBBSemantic proximity Read ↗

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity Read ↗

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodiesSemantic proximity Read ↗

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.